Publications by authors named "David B Hall"

Claim this Profile
I
Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis.
Hervé Bachelez, Siew-Eng Choon, Slaheddine Marrakchi, A David Burden, Tsen-Fang Tsai, David B Hall

N Engl J Med· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Brian G Feagan, Julián Panés, Marc Ferrante, Arthur Kaser, Geert R D'Haens, David B Hall

Lancet Gastroenterol Hepatol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
Dominique Baeten, Mikkel Østergaard, James Cheng-Chung Wei, Joachim Sieper, Pentti Järvinen, David B Hall

Ann Rheum Dis· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Brian G Feagan, William J Sandborn, Geert D'Haens, Julián Panés, Arthur Kaser, David B Hall

Lancet· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women.
Sarah Palmer, Valerie F Boltz, Jeremy Y Chow, Neil A Martinson, James A McIntyre, David B Hall

Antivir Ther· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Planning and core analyses for periodic aggregate safety data reviews.
H Amy Xia, Brenda J Crowe, Robert C Schriver, Manfred Oster, David B Hall

Clin Trials· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score.
Jonathan M Schapiro, Joseph Scherer, Charles A Boucher, John D Baxter, Clemens Tilke, David B Hall

Antivir Ther· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team.
Brenda J Crowe, H Amy Xia, Jesse A Berlin, Douglas J Watson, Hongliang Shi, David B Hall

Clin Trials· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.
James A McIntyre, Mark Hopley, Daya Moodley, Marie Eklund, Glenda E Gray, David B Hall

PLoS Med· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary metabolites.
David B Hall, Thomas R Macgregor

HIV Clin Trials· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.
John D Baxter, Jonathan M Schapiro, Charles A B Boucher, Veronika M Kohlbrenner, David B Hall

J Virol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seeking ethical designs for HIV clinical trials in treatment-experienced patients: an industry perspective.
Douglas L Mayers, Jain Chung, Veronika M Kohlbrenner, David B Hall, Ralph A DeMasi

AIDS Res Hum Retroviruses· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A group sequential adaptive treatment assignment design for proof of concept and dose selection in headache trials.
David B Hall, Ulrich Meier, Hans-Cristoph Diener

Contemp Clin Trials· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
Frank van Leth, Casper B Huisamen, Roberto Badaro, Bernard Vandercam, Joss de Wet, David B Hall

J Acquir Immune Defic Syndr· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
Frank van Leth, Prahpan Phanuphak, Erik Stroes, Brian Gazzard, Pedro Cahn, David B Hall

PLoS Med· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.
Gail Skowron, Gifford Leoung, David B Hall, Patrick Robinson, Ronald Lewis

J Acquir Immune Defic Syndr· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.
Julio S G Montaner, Pedro Cahn, Carlos Zala, Lidia I Casssetti, Marcelo Losso, David B Hall

J Acquir Immune Defic Syndr· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac.
Daniel E Furst, Karen S Kolba, Roy Fleischmann, Joel Silverfield, Maria Greenwald, David B Hall

J Rheumatol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis